Blood Cancer Awareness – Acute Myeloid Leukemia (AML)
Dr. Eytan M. Stein, Hematologic Oncologist at Memorial Sloan Kettering Cancer Center discusses the current state of acute myeloid leukemia (AML), the importance of testing for genetic mutations, and the emergence of targeted treatments. He is joined by Shirley, a patient living with IDH1-mutated AML.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Eytan M. Stein, MD is an Associate Attending Physician, Clinical Investigator and Director of the Program for Drug Development in Leukemia on the Leukemia Service at Memorial Sloan Kettering Cancer Center. He conducts novel, phase I clinical trials of compounds that target the genetic and epigenetic basis of myeloid malignancies. Dr. Stein led the clinical studies of the IDH2 inhibitor Enasidenib and the IDH1 Inhibitor Ivosidenib in patients with relapsed and refractory AML that led to their FDA approval in 2017 and 2018, respectively. He also leads a variety of phase 1 clinical trials and serves as the lead investigator at Memorial Sloan Kettering for the BEAT AML master clinical trial. His current research focuses on elucidating mechanisms of resistance to IDH inhibitors and the use of Menin inhibitors in patients with MLL-rearranged acute leukemia. His work has been published in journals such as Nature, Nature Medicine, The New England Journal of Medicine, JAMA Oncology, Cancer Discovery and Blood. In addition, he serves on the Editorial Boards of Blood and Leukemia and Lymphoma.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
